logo
Plus   Neg
Share
Email

Eli Lilly: Taltz Shows Efficacy In Phase 4 Study - Quick Facts

Eli Lilly and Company (LLY) said Taltz (ixekizumab), an IL-17A inhibitor, met the primary and all major secondary endpoints in the phase 4 IXORA-R study. The study involved 1,027 patients with moderate to severe plaque psoriasis. At 12 weeks, Taltz showed superiority in the proportion of patients achieving complete skin clearance compared to TREMFYA, a IL-23/p19 inhibitor. The safety data was consistent with prior results.

The company plans to submit detailed data from the study at scientific meetings and in peer-reviewed journals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bank of America Corp. (BAC) reported net income of $5.8 billion, or $0.56 per share, for the third quarter of fiscal 2019. The company's third-quarter results included Merchant Services Joint Venture impairment Charge of $2.1 billion or $0.19 per share. Excluding the impairment charge, net income was... The Libra Association, formed by major financial partners of Facebook's Libra cryptocurrency project, formalized the association at the inaugural Libra Council meeting of the members at its headquarters in Geneva, Switzerland. The current 21 member organizations formally signed onto the Libra Association charter, elected the Board of Directors, and appointed the executive team. Department store chain Kohl's Corp. has unveiled its Kohl's Cares holiday collection that includes the Disney Frozen 2 and Holiday Character bundles. The company's philanthropic program, Kohl's Cares, sells children's books as well as toys and donates the entire profit to charitable initiatives nationwide.
Follow RTT
>